- Visibility 340 Views
- Downloads 358 Downloads
- Permissions
- DOI 10.18231/j.ijpca.v.12.i.2.4
-
CrossMark
Potassium-competitive acid blockers (PCABs): A novel era in gastric acid suppression
- Author Details:
-
Sourabh D Jain *
-
Ankit Agrawal
-
Arun K Gupta
Sourabh D Jain *
Ankit Agrawal
Potassium-competitive acid blockers (PCABs) represent a new class of drugs that offer a promising alternative to traditional proton pump inhibitors (PPIs) for the treatment of acid-related gastrointestinal disorders such as gastroesophageal reflux disease (GERD), peptic ulcer disease, and Helicobacter pylori infections. Unlike PPIs, which irreversibly inhibit the H⁺/K⁺-ATPase pump, PCABs act by reversibly and competitively blocking the potassium-binding site of the gastric proton pump, resulting in rapid, potent, and sustained suppression of gastric acid secretion. This unique mechanism provides a faster onset of action, longer duration, and improved acid control, especially during nocturnal periods. Moreover, PCABs are not influenced by meal timing or the need for activation in acidic environments, making them more predictable in therapeutic response. Vonoprazan is currently the most extensively studied PCAB, with several others under clinical development. This review highlights the pharmacological advantages, clinical efficacy, safety profile, and potential therapeutic roles of PCABs, underscoring their significance in advancing the management of acid-related diseases and paving the way for a novel era in gastric acid suppression therapy.
References
- Ashida K, Kawakami K, Suzuki M. Pharmacological characteristics of vonoprazan, a novel potassium-competitive acid blocker. Curr Pharma Design, 2016;22(14):2045–53.
- Barkun AN, Bardou M. Proton pump inhibitors and gastric mucosal protection: A review of the literature. Therap Adv Gastroenterol, 2019;12:1756284819873773.
- Chey W D, Leontiadis G.I. Potassium-competitive acid blockers for the treatment of acid-related disorders: A review. Gastroenterol Hepatol. 2019;15(1):44–53.
- Dickman R, Fuchs CS. Advances in acid suppression therapy for GERD: Clinical implications. World J Gastroenterol, 2018;24(37):4247–57.
- Freston JW, Katz PO. Pharmacodynamics and clinical efficacy of potassium-competitive acid blockers. Clin Therap, 2017;39(6):1163–71.
- Graham DY, Lee YCJ. Update on the treatment of Helicobacter pylori infection. Curr Opin Gastroenterol. 2015;31(6):567–73.
- Hori Y, Matsukawa J. Pharmacology of potassium-competitive acid blockers: A review. Front Pharmacol. 2017;8:1–10.
- Hsu PI, Wu DC. Novel acid suppressants for Helicobacter pylori eradication: Role of potassium-competitive acid blockers. J Gastroenterol Hepatol, 2018;33(1):73–80.
- Iwakiri R, Haruma K. Role of potassium-competitive acid blockers in managing GERD. Diges Dis Sci. 2018;63(2):267–75.
- Jung HK, Kim SE. The efficacy and safety of vonoprazan in acid- related disorders: A systematic review. J Neurogastroenterol Motility, 2019;25(2):179–89.
- Kanno T, Ohta T. Vonoprazan fumarate: A novel potassium- competitive acid blocker. Expert Opin Investig Drugs, 2016;25(12):1343–51.
- Kato M, Yamasaki H. Comparison of acid suppression by PPIs and PCABs: Clinical significance. Alimentary Pharmacol Therap, 2020;51(6):585–93.
- Kinoshita Y, Ishimura N. Potassium-competitive acid blockers in gastroesophageal reflux disease. Diges Endos, 2018;30(5):566–73.
- Laine L, Jensen DM. Management of NSAID-associated upper GI toxicity: The role of acid suppression. Alimen Pharmacol Therap, 2017;45(3):324–32.
- Lee SP, Kim JH. Efficacy of vonoprazan in Helicobacter pylori eradication therapy. Gut and Liver, 2017;13(4):374–81.
- Li SC, Owyang C. Potassium-competitive acid blockers: Mechanisms and clinical applications. Curr Gastroenterol Rep. 2017;19(10):49.
- Mönkemüller K, Neumann H. Novel acid suppression therapies: Are PCABs superior to PPIs? Expert Rev Clin Pharmacol, 2018;11(4):325–31
- Murakami K, Sakurai Y. Clinical pharmacology of vonoprazan fumarate. Expert Opin Drug Metab Toxicol, 2016;12(8):911–19.
- Naito Y, Yoshikawa T. Protective effect of PCABs against NSAID- induced gastric injury. World J Gastroenterol, 2017;23(33):6021–
- Oshima T, Miwa H. Potassium-competitive acid blockers: A new approach to acid-related diseases. Curr Opin Pharmacol, 2018;40:20–7.
- Sakurai Y, Nishimura A. Vonoprazan fumarate: Clinical efficacy and safety. Therap Adv Gastroenterol, 2016;9(6):857–67.
- Sakurai Y, Nishimura A. Role of potassium-competitive acid blockers in Helicobacter pylori eradication therapy. World J Gastroenterol. 2017;23(7):1156–63.
- Shin JM, Kim N. Potassium-competitive acid blockers: A novel class of gastric acid suppressants. Gut and Liver, 2019;13(2):111–9.
- Sugano K, Tack J. PCABs: The future of acid suppression therapy. J Gastroenterol, 2018;53(3):267–75.
- Takeuchi T, Tanaka Y. Acid suppression and clinical outcomes with vonoprazan versus PPIs. Digestive Dis, 2019;37(5):374–81
- Tarnawski AS, Ahluwalia A. Advances in acid suppression: PCABs versus PPIs. Curr Gastroenterol Rep. 2018;20(8):39.
- Umegaki E, Shimizu T. Pharmacokinetics and pharmacodynamics of PCABs in acid-related diseases. Clin Pharmacokinetics, 2017;56(3):243–56.
- Vakil N, Zanten SV. Efficacy of potassium-competitive acid blockers for erosive esophagitis. Am J Gastroenterol. 2019;114(9):1414–21.
- Yamasaki H, Kato M. Safety and tolerability of vonoprazan: A review. Expert Opin Drug Saf, 2020;19(8):1005–12. 109 Jain et al / International Journal of Pharmaceutical Chemistry and Analysis 2025;12(2):105-109
- Yoshikawa T, Naito Y. Potassium-competitive acid blockers in clinical practice: Current status and perspectives. Gastroenterol Res Pract, 2018;26;(11):1–10.